title: Rome Consensus Conference - statement; human papilloma virus diseases in males.
abstract: BACKGROUND
  Human Papillomavirus (HPV) is a very resistant, ubiquitous virus that can survive in the environment without a host. The decision to analyse HPV-related diseases in males was due to the broad dissemination of the virus, and, above all, by the need to stress the importance of primary and secondary prevention measures (currently available for women exclusively). The objective of the Consensus Conference was to make evidence-based recommendations that were designed to facilitate the adoption of a standard approach in clinical practice in Italy.
  
  
  METHODS
  The Sponsoring Panel put a series of questions to the members of the Scientific Committee who prepared a summary of the currently available information, relevant for each question, after the review and grading of the existing scientific literature. The summaries were presented to a Jury, also called multidisciplinary Consensus Panel, who drafted a series of recommendations.
  
  
  RESULTS
  The prevalence of HPV in males ranges between 1.3-72.9%;. The prevalence curve in males is much higher than that in females and does not tend to decline with age. Women appear to have a higher probability of acquiring HPV genotypes associated with a high oncogenic risk, whereas in males the probability of acquiring low- or high-risk genotypes is similar. The HPV-related diseases that affect males are anogenital warts and cancers of the penis, anus and oropharynx. The quadrivalent vaccine against HPV has proved to be effective in preventing external genital lesions in males aged 16-26 years in 90.4%; (95%; CI: 69.2-98.1) of cases. It has also proved to be effective in preventing precancerous anal lesions in 77.5%; (95%; CI: 39.6-93.3) of cases in a per-protocol analysis and in 91.7%; (95%; CI: 44.6-99.8) of cases in a post-hoc analysis. Early ecological studies demonstrate reduction of genital warts in vaccinated females and some herd immunity in males when vaccine coverage is high, although males who have sex with males gained no benefit at all. Males with an immunodeficiency disease are at greater risk of developing disease. Infertility seems to be caused by HPV in some cases. Studies demonstrate vaccination to both genders can be more efficacious and social equity matters are to be taken into consideration.
  
  
  CONCLUSIONS
  The Jury made Recommendations based on the scientific evidence presented by the Scientific Committee. Accordingly, for prevention purposes and social fairness and equality, as both sexes are affected by the disease, the vaccination of 12-year-old males against HPV should be recommended in order to guaranty protection to everyone. Aspects related to healthcare policy and economic sustainability, are to be discussed by respective public system representatives. More campaigns to raise awareness through all institutional channels are needed, not only regarding anogenital warts, but for HPV-related diseases in general in males in accordance to new scientific evidences.
authors: Institute/Department of Endocrinology, La Sapienza University, Rome, Italy. andrea.lenzi@uniroma1.it
authors: Andrea
authors: A
authors: Lenzi
authors: Vincenzo
authors: V
authors: Mirone
authors: Vincenzo
authors: V
authors: Gentile
authors: Riccardo
authors: R
authors: Bartoletti
authors: Vincenzo
authors: V
authors: Ficarra
authors: Carlo
authors: C
authors: Foresta
authors: Luciano
authors: L
authors: Mariani
authors: Sandra
authors: S
authors: Mazzoli
authors: Saverio G
authors: SG
authors: Parisi
authors: Antonio
authors: A
authors: Perino
authors: Mauro
authors: M
authors: Picardo
authors: Carla Maria
authors: CM
authors: Zotti
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D015995:Prevalence; D011322:Primary Prevention; D012307:Risk Factors; D017678:Sex Distribution; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines
references: J Clin Microbiol. 2007 Jan;45(1):248-51
references: 17093029
references: Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2036-43
references: 18708396
references: Clin Infect Dis. 2005 Sep 1;41(5):612-20
references: 16080082
references: Lancet. 2007 May 19;369(9574):1693-702
references: 17512854
references: Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):101-6
references: 11219765
references: Fertil Steril. 2006 Sep;86(3):765-7
references: 16782096
references: J Infect Dis. 2010 May 15;201(10):1498-508
references: 20367457
references: MMWR Morb Mortal Wkly Rep. 2010 May 28;59(20):630-2
references: 20508594
references: Vaccine. 2009 May 29;27 Suppl 1:A17-23
references: 19480955
references: Lancet. 2007 Jun 2;369(9576):1861-1868
references: 17544766
references: J Adolesc Health. 2010 Apr;46(4 Suppl):S12-9
references: 20307839
references: Ig Sanita Pubbl. 2010 Nov-Dec;66(6):733-56
references: 21358773
references: Lancet. 2009 Jul 25;374(9686):301-14
references: 19586656
references: Gynecol Obstet Fertil. 2010 Mar;38(3):199-204
references: 20189438
references: J Med Virol. 2010 Aug;82(8):1424-30
references: 20572068
references: N Engl J Med. 2007 May 10;356(19):1928-43
references: 17494926
references: Int J Urol. 2010 Jun;17(6):563-8
references: 20345431
references: Lancet Infect Dis. 2006 Jan;6(1):21-31
references: 16377531
references: Sex Transm Infect. 2009 Jun;85(3):221-5
references: 19066196
references: Sex Transm Dis. 1994 Mar-Apr;21(2):76-82
references: 9071416
references: Transplant Proc. 1991 Apr;23(2):1771-2
references: 2053149
references: J Med Virol. 2010 Apr;82(4):592-6
references: 20166175
references: Sex Transm Dis. 2001 May;28(5):277-80
references: 11354266
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/52-61
references: 16950018
references: Eur J Cancer. 2005 Jan;41(2):297-305
references: 15661556
references: J Med Virol. 2008 Jul;80(7):1275-81
references: 18461608
references: Cancer Prev Res (Phila). 2009 Oct;2(10):868-78
references: 19789295
references: Int J Cancer. 2003 Dec 10;107(5):811-6
references: 14566832
references: J Infect Dis. 2004 Aug 1;190(3):468-76
references: 15243918
references: Int J Androl. 2011 Jun;34(3):242-6
references: 20522126
references: Bull World Health Organ. 1997;75(1):69-80
references: 9141752
references: BMJ. 2001 Aug 11;323(7308):334-6
references: 11498496
references: J Infect Dis. 2007 Oct 15;196(8):1146-52
references: 17955432
references: Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1710-6
references: 16030106
references: J Clin Virol. 2005 Mar;32 Suppl 1:S43-51
references: 15753011
references: J Infect Dis. 2006 Oct 15;194(8):1044-57
references: 16991079
references: BMJ. 2010 Jul 20;341:c3493
references: 20647284
references: Ann Oncol. 2010 Mar;21(3):448-458
references: 20176693
references: Lancet. 1998 Jun 20;351(9119):1833-9
references: 9652666
references: Fertil Steril. 1997 Jun;67(6):1152-5
references: 9176459
references: AIDS. 2002 Mar 29;16(5):781-6
references: 11964535
references: Epidemiology. 2010 Jan;21(1):31-7
references: 19907332
references: Sex Transm Infect. 2009 Dec;85(7):499-502
references: 19837728
references: J Natl Cancer Inst. 1996 Aug 7;88(15):1060-7
references: 8683637
references: Br J Cancer. 2002 Mar 4;86(5):705-11
references: 11875730
references: J Natl Cancer Inst. 1993 Jan 6;85(1):19-24
references: 8380060
references: Eur J Obstet Gynecol Reprod Biol. 2008 Mar;137(1):88-91
references: 17485158
references: Sex Transm Dis. 1993 Nov-Dec;20(6):321-8
references: 8108754
references: Int J STD AIDS. 2000 Feb;11(2):80-4
references: 10678474
references: N Engl J Med. 2011 Feb 3;364(5):401-11
references: 21288094
references: Am J Epidemiol. 2003 Feb 1;157(3):218-26
references: 12543621
references: Obstet Gynecol. 2001 Mar;97(3):357-60
references: 11239636
references: J Am Acad Dermatol. 2002 Sep;47(3):351-7
references: 12196743
references: Sex Transm Infect. 2002 Jun;78(3):215-8
references: 12238658
references: J Acquir Immune Defic Syndr. 2010 Jan;53(1):111-6
references: 19779357
references: Vaccine. 2006 Aug 31;24 Suppl 3:S3/178-86
references: 16950005
references: Int J STD AIDS. 2004 Nov;15(11):740-3
references: 15537460
references: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1528-33
references: 15941967
references: J Infect Dis. 2003 Apr 1;187(7):1064-70
references: 12660920
references: J Infect Dis. 2004 Feb 15;189(4):677-85
references: 14767822
references: Urology. 2005 Feb;65(2):251-5
references: 15708032
references: Public Health Genomics. 2009;12(5-6):291-307
references: 19684442
references: Epidemiol Rev. 1988;10:122-63
references: 2852116
references: J Infect Dis. 1999 Nov;180(5):1415-23
references: 10515798
references: MMWR Recomm Rep. 2006 Aug 4;55(RR-11):1-94
references: 16888612
references: Lancet. 2007 Mar 24;369(9566):979-80
references: 17387782
references: J Infect Dis. 2007 Oct 15;196(8):1137-45
references: 17955431
references: Lancet. 2009 Jun 6;373(9679):1949-57
references: 19493565
references: Int J Cancer. 2010 Jan 15;126(2):572-7
references: 19626601
references: J Infect Chemother. 2005 Dec;11(6):270-3
references: 16369732
references: Genitourin Med. 1994 Aug;70(4):240-6
references: 7959707
references: N Engl J Med. 2007 May 10;356(19):1915-27
references: 17494925
references: J Infect Dis. 2007 Oct 15;196(8):1128-36
references: 17955430
references: Infect Agent Cancer. 2008 Dec 16;3:14
references: 19087272